Aneurysm characteristics, treatment complications, and morbidity and mortality in patients treated with WEB DL and WEB SL (and SLS)

	WEB DL	WEB SL/SLS	P Value
Patients	30	32
Age (mean) (yr)	55.6 ± 8.9	57.4 ± 10.3	.86
Female	24/30 (80.0%)	16/32 (50.0%)	.20
Aneurysms	31	32
Ruptured	2/31 (6.5%)	5/32 (15.6%)	.42
AcomA	4/31 (12.9%)	12/32 (37.5%)	.04
Aneurysm <10 mm	21/31 (67.7%)	31/32 (96.9%)	.002
Neck >4 mm	29/31 (96.5%)	28/32 (87.5%)	.67
Antiplatelet treatmenta
Before treatment	4/30 (13.3%)	11/32 (34.4%)	.07
During treatment	22/30 (73.3%)	20/32 (62.5%)	.42
After treatment	26/30 (86.7%)	22/32 (68.8%)	.13
Treatment feasibility	30/31 (96.8%)	32/32 (100.0%)	.49
Adjunctive treatment	4/30 (13.3%)	3/32 (9.4%)	.70
Adverse events
Device problems	3/30 (10.0%)	2/32 (6.3%)	.66
TEb	7/30 (23.3%)	3/32 (9.4%)	.17
IOR	1/30 (3.3%)	0/32 (0.0%)	.48
Morbidity/mortality
Morbidity	1/30 (3.3%)	1/32 (3.1%)	1
Mortality	0/30 (0.0%)	0/32 (0.0%)	1

Note:—TE indicates thromboembolic event/appearance of thrombus; IOR, intraoperative rupture.

^aOne or 2 medications.

^bDL group: no clinical deficit in 3, transient deficits in 3, permanent deficit in 1. SL group: no deficit in 1, transient deficits in 2.